Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with SBRT and Surgery in Pulmonary Recurrence of Osteosarcoma
NCT06492954Phase 1Recruiting
- Sponsor
- Emory University
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in osteosarcoma (OS), sponsored by Emory University. Primary endpoints: Number of participants with Dose limiting toxicity at Dose Level 1 at 1 year and Number of participants with Dose limiting toxicity at Dose Level 2 at 1 year. Started Oct 2026; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT06492954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492954.